Skip to content

The Medacta International GMK Sphere Cementless Post-Marketing Surveillance Study

A Prospective, Multicentre, International, Post-marketing, Longitudinal, Observational Cohort Study to Monitor the Performances of GMK Sphere Cementless Knee Prosthesis

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05003414
Enrollment
200
Registered
2021-08-12
Start date
2020-01-14
Completion date
2032-12-31
Last updated
2025-09-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Arthritis, Avascular Necrosis, Poly-arthritis, Rheumatoid Arthritis, Traumatic Arthritis

Brief summary

This is a Post-Marketing Surveillance study of GMK Sphere cementless knee prosthesis.

Interventions

DEVICEGMK Sphere cementless Knee Replacement

Performance of Total Knee Arthroplasty (TKA) with GMK Sphere cementless Knee Replacement

Sponsors

Medacta International SA
Lead SponsorINDUSTRY

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* A disabled or severely disabled joint as a result of arthritis, traumatic arthritis, rheumatoid arthritis, poly-arthritis or avascular necrosis * Patients between the age of 18 and 80 at the time of consent * Listed for total knee replacement surgery. * Patients who are willing and able to give informed written consent

Exclusion criteria

* Progressive local or systemic infection * Muscular loss, neuromuscular disease or vascular deficiency of the affected limb, making the operation unjustifiable * Severe instability secondary to advance destruction of condralar structures or loss of integrity of the medial or lateral ligament * Those whose prospects for a recovery to independent mobility would be compromised by known coexistent, medical problems * Patient whose BMI exceeds 40 * Any case not described in the inclusion criteria

Design outcomes

Primary

MeasureTime frameDescription
Survival rate10 yearsKaplan Meier method

Secondary

MeasureTime frameDescription
Clinical outcome: Knee Society scorePreop and 1, 2, 5, 10 years postopKnee Society Score (KSS): evaluates pain, in a total of 50 points, stability, 25 points, and range of motion, 25 points. The maximum score of 100 points is reached when there is no pain, with good alignment of the knee in extension, and at least 125° of range of motion, without any anteroposterior or mediolateral instability.
Patient-reported outcome: Forgotten Joint Score1, 2, 5, 10 years postopForgotten Joint Score (FJS) is a patient-reported outcome measure intended to determine a patient's ability to forget about their affected joint after surgery or treatment.It consists of 12 questions and is scored on a 0-100 scale. The higher the score, the less the patient is aware of their affected joint when performing daily activities
Radiographic performance of the implants looking for radiolucencies, migration, loosening, subsidenceImmediately postop + 1, 2, 5, 10 years postopPresence of radiolucencies, migration, loosening, subsidence
Intraoperative and postoperative Adverse eventsIntraop + Immediately postop + 1, 2, 5, 10 years postopIntraoperative and postoperative adverse events

Countries

France, Switzerland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026